Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAA868 versus apixaban dose-ranging study in atrial fibrillation
NL-OMON46376Phase 2Withdrawn
- Sponsor
- Novartis
- Start
- Jan 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of abelacimab in Atrial fibrillation (AFib) and atrial flutter (AFL) (4 arms), sponsored by Novartis. Primary endpoint: FXI inhibition at trough on Day 91. Planned start Jan 2018; status: withdrawn.
02
Drugs
abelacimab
03
Conditions
Atrial fibrillation (AFib)atrial flutter (AFL)
Beyond the preview
Go deeper on NL-OMON46376.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46376.